Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

45% Stake in Shanghai Schering-Plough JV For Sale

publication date: May 23, 2008

Two China-based minority owners of the joint venture known as Shanghai Schering-Plough Industry Corp. Ltd. have announced their intentions to sell their participation in the entity. The majority owner, the giant pharma Schering-Plough (NYSE: SGP), will retain its 55% interest in the JV, and the big pharma will also have right of first refusal on buying the 45% minority stake. The asking price for the 45% piece of Shanghai Schering-Plough is 66.3 million RMB ($9.6 million).  More details...

Stock Symbol: (NYSE: SGP)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here